Report cover image

Prothrombin Complex Concentrate PCC Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Dec 01, 2024
Length 158 Pages
SKU # FOB19410753

Description

Prothrombin Complex Concentrate PCC Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Prothrombin Complex Concentrate Market

The prothrombin complex concentrate market size was valued at USD 695.3 million in 2019, and the market is now projected to grow from USD 695.3 million in 2019 to USD 2385.3 million by 2032, exhibiting a CAGR of 9.6% during the forecast period of 2019-2032.

Pandemic has heightened call for blood and plasma merchandise, main to adjustments in plasma-derived product buying patterns. Major PCC manufacturers, along with Grifols and CSL, are experiencing increased segmental revenue due to increased plasma center productiveness and Kcentra's double-digit growth, that is expected to positively impact the overall market.

PCC is a popular anticoagulation-reversal remedy because of its benefits over other options like FFP and Vitamin Kl. It eliminates the need for blood matching and thawing, reducing management time. PCC offers shorter penetration time, better performance, and is needed in much less quantity. It also has minimal hazard of viral or pathogen transmission, making it a favored choice and doubtlessly contributing to marketplace expansion. These benefits have brought about increased choice for PCC in pressing warfarin-reversals.

The marketplace trend is that specialize in increasing plasma facilities, main to improved manufacturing techniques for plasma proteins. Major players are acquiring home companies to gain from their plasma centers and decorate manufacturing capacity. Grifols S.A. Is expected to benefit get access to Biotest's plasma collection centers and boom its plasma protein deliver for healing purposes. The growth in manufacturing and delivery of thing IX complex, in particular in the course of the COVID-19 pandemic, is predicted to boost the prothrombin complex concentrate market growth.

Comprehensive Analysis of Prothrombin Complex Concentrate Market

The PCC market segment is divided into 3-factor PCC and 4-factor PCC, with the 4-factor segment accounting for the majority in 2019. The 4-factor segment is driven by improved penetration of 4-factor PCC brands like Kcentra & Beriplex in emerging countries and their clinically proven efficacy for urgent warfarin reversal. The 3-factor segment is expected to grow due to the rising prevalence of hemophilia and increasing demand for Profilnine SD and Bebulin. The market is also segmented into acquired coagulation factor deficiency and congenital coagulation factor deficiency. The acquired coagulation factor deficiency segment generated the highest revenue in 2019 and is expected to experience significant growth due to increasing cases of life-threatening bleeding, induced coagulation factor deficiency during surgical procedures, and new product launches. The congenital coagulation factor deficiency segment is expected to gain momentum due to increased sales of Kcentra during the COVID-19 crisis. The end user segment is primarily hospitals and ambulatory surgical centres, with hospitals and ambulatory surgery expected to dominate the market due to rising demand for prothrombin complex concentrate, government recommendations, and increased plasma product purchases. Specialty clinics are expected to grow due to the increasing number of surgeons and privately owned clinics. The others segment, including urgent care centres, emergency trauma centres, and physicians' offices, is likely to grow due to increased investment in healthcare facilities.

The North America region lead the prothrombin complex concentrate market share by benefitting a market size of USD 305.9 million in 2019 due to aid of essential manufacturers' strategic presence, the USFDA's green sign for 4-factor PCC, and Kcentra's increasing income. Canada's buy of 3,728,656 1. U of element IX in 2018 is expected to similarly raise the marketplace in North America.

CSL Behring holds the largest market share in sales due to Kcentra sales. In 2017, it released Kcentra in Japan, with round 2,800 sufferers the usage of it in 2019. Key corporations consist of Grifols, S.A., CSL Behring, Octopharma AG, Sanquin, Kedrion S.P.A, China Biologic Products Holdings, Inc., and Takeda Pharmaceutical Company Limited.

In March 2019, Grifols S.A. Entered a strategic agreement to govern 26.2% of Shanghai RAAS in trade for a non-minority share in Grifols Diagnostic Solutions, aiming to enhance its plasma-derived merchandise in China.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD million)

By Product Type

3-factor

4-factor

By Application

Acquired Coagulation Factor Deficiency

Congenital Coagulation Factor Deficiency

By End User

Hospital & Ambulatory Surgical Centers

Specialty Clinics

Others

By Geography

North America (the U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

The Middle East& Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

158 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics – Global PCC Market
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Coagulation Factor Deficiency – For Key Countries
4.2. Recent Industry Developments – Partnerships, Mergers & Acquisitions
4.3. Regulatory Scenario – For Key Countries
4.4. Analysis in Relation to Alternatives to PCC
4.5. Global PCC Market: Reimbursement Scenario & Key Industry Trends
5. Global Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Product
5.2.1. 3-factor PCC
5.2.2. 4-factor PCC
5.3. Market Analysis, Insights and Forecast – By Application
5.3.1. Acquired coagulation factor deficiency
5.3.2. Congenital coagulation factor deficiency
5.4. Market Analysis, Insights and Forecast – By End User
5.4.1. Hospitals
5.4.2. Ambulatory Surgical Centers
5.4.3. Others
5.5. Market Analysis, Insights and Forecast – By Geography
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Product
6.2.1. 3-factor PCC
6.2.2. 4-factor PCC
6.3. Market Analysis, Insights and Forecast – By Application
6.3.1. Acquired coagulation factor deficiency
6.3.2. Congenital coagulation factor deficiency
6.4. Market Analysis, Insights and Forecast – By End User
6.4.1. Hospitals
6.4.2. Ambulatory Surgical Centers
6.4.3. Others
6.5. Market Analysis, Insights and Forecast – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Product
7.2.1. 3-factor PCC
7.2.2. 4-factor PCC
7.3. Market Analysis, Insights and Forecast – By Application
7.3.1. Acquired coagulation factor deficiency
7.3.2. Congenital coagulation factor deficiency
7.4. Market Analysis, Insights and Forecast – By End User
7.4.1. Hospitals
7.4.2. Ambulatory Surgical Centers
7.4.3. Others
7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
7.5.1. U.K.
7.5.2. Germany
7.5.3. France
7.5.4. Italy
7.5.5. Spain
7.5.6. Scandinavia
7.5.7. Rest of Europe
8. Asia Pacific Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Product
8.2.1. 3-factor PCC
8.2.2. 4-factor PCC
8.3. Market Analysis, Insights and Forecast – By Application
8.3.1. Acquired coagulation factor deficiency
8.3.2. Congenital coagulation factor deficiency
8.4. Market Analysis, Insights and Forecast – By End User
8.4.1. Hospitals
8.4.2. Ambulatory Surgical Centers
8.4.3. Others
8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of APAC
9. Latin America Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast – By Product
9.2.1. 3-factor PCC
9.2.2. 4-factor PCC
9.3. Market Analysis, Insights and Forecast – By Application
9.3.1. Acquired coagulation factor deficiency
9.3.2. Congenital coagulation factor deficiency
9.4. Market Analysis, Insights and Forecast – By End User
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Others
9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of LATAM
10. Middle East & Africa Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis, Insights and Forecast – By Product
10.2.1. 3-factor PCC
10.2.2. 4-factor PCC
10.3. Market Analysis, Insights and Forecast – By Application
10.3.1. Acquired coagulation factor deficiency
10.3.2. Congenital coagulation factor deficiency
10.4. Market Analysis, Insights and Forecast – By End User
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Others
10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
10.5.1. South Africa
10.5.2. GCC
10.5.3. Rest of MEA
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Product offerings, SWOT analysis, Recent developments, Strategies, Financials (based on availability))
11.5.1. Grifols SA
11.5.1.1. Overview,
11.5.1.2. Product offerings,
11.5.1.3. SWOT analysis,
11.5.1.4. Recent developments,
11.5.1.5. Strategies,
11.5.1.6. Financials (based on availability)
11.5.2. CSL Behring
11.5.2.1. Overview,
11.5.2.2. Product offerings,
11.5.2.3. SWOT analysis,
11.5.2.4. Recent developments,
11.5.2.5. Strategies,
11.5.2.6. Financials (based on availability)
11.5.3. Octapharma AG
11.5.3.1. Overview,
11.5.3.2. Product offerings,
11.5.3.3. SWOT analysis,
11.5.3.4. Recent developments,
11.5.3.5. Strategies,
11.5.3.6. Financials (based on availability)
11.5.4. Sanquin
11.5.4.1. Overview,
11.5.4.2. Product offerings,
11.5.4.3. SWOT analysis,
11.5.4.4. Recent developments,
11.5.4.5. Strategies,
11.5.4.6. Financials (based on availability)
11.5.5. Shire
11.5.5.1. Overview,
11.5.5.2. Product offerings,
11.5.5.3. SWOT analysis,
11.5.5.4. Recent developments,
11.5.5.5. Strategies,
11.5.5.6. Financials (based on availability)
11.5.6. Kedrion S.p.A
11.5.6.1. Overview,
11.5.6.2. Product offerings,
11.5.6.3. SWOT analysis,
11.5.6.4. Recent developments,
11.5.6.5. Strategies,
11.5.6.6. Financials (based on availability)
11.5.7. China Biologic Products Holdings, Inc.
11.5.7.1. Overview,
11.5.7.2. Product offerings,
11.5.7.3. SWOT analysis,
11.5.7.4. Recent developments,
11.5.7.5. Strategies,
11.5.7.6. Financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us